抑郁与类风湿关节炎生物制剂治疗反应之间的关系:英国风湿病学会生物制剂注册登记分析
基于英国风湿病学会生物制剂注册登记中18421例接受生物制剂治疗的类风湿关节炎患者,分析基线抑郁症状与1年治疗反应及疾病活动度的关系。结果显示基线抑郁症状与1年获得良好治疗反应的几率降低20-40%相关,并与随访期间疾病活动度改善减少相关。作者认为抑郁应作为常规临床管理的一部分以优化治疗结局。
要点
- 基线抑郁症状与1年良好治疗反应几率降低20-40%相关。
- 基线抑郁症状与随访期间疾病活动度改善减少相关。
- 作者认为抑郁应作为常规临床管理的一部分以优化治疗结局。
核心结论
- 生物制剂治疗开始时存在抑郁症状可能降低获得良好治疗反应的几率,并减少疾病活动度随时间的改善。
- 作者认为抑郁应作为常规临床管理的一部分以优化治疗结局。
研究设计与样本
- 基于英国风湿病学会生物制剂注册登记的数据分析,纳入18421例接受生物制剂治疗的类风湿关节炎患者。
- 抑郁症状通过三种评估之一识别:报告抑郁病史、医学结局调查36项简表或EuroQol五维度量表。
- 采用逻辑回归分析基线抑郁症状与1年时良好治疗反应几率的关系。
- 采用多水平模型分析基线抑郁症状与1年随访期间疾病活动度结局的关联,校正年龄、性别、疾病病程、合并症及基线疾病活动度和躯体残疾。
主要发现
- 生物制剂治疗开始时抑郁症状与1年时获得良好治疗反应的几率降低20-40%相关。
- 基线抑郁症状还与随访期间疾病活动度改善减少相关。
- 有抑郁病史或根据EuroQol五维度量表报告抑郁症状的患者,在1年随访期间压痛关节数、肿胀关节数、患者总体评估和ESR的改善减少。
- 根据36项简表报告抑郁症状的患者,压痛关节数和肿胀关节数改善减少,但ESR或患者总体评估无此表现。
临床怎么用
- 作者认为抑郁应作为常规临床管理的一部分以优化治疗结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the relationship between depressive symptoms and treatment response and disease activity in RA over a 1-year follow-up. METHODS: Data from the British Society for Rheumatology Biologics Register were used, representing 18 421 RA patients receiving biologic treatment. Depressive symptoms were identified through one of three assessments: reporting a history of depression, the Medical Outcomes Survey 36-item Short Form or the EuroQol five-dimension scale. Logistic regression analyses examined the relationship between baseline depressive symptoms and odds of good treatment response by 1 year. Multilevel models addressed the association between baseline depressive symptoms and disease activity outcomes over 1-year follow-up, adjusting for age, gender, disease duration, comorbidities and baseline disease activity and physical disability. RESULTS: Depression symptoms at biologic treatment initiation were associated with 20-40% reduced odds of achieving a good treatment response at 1 year. Depressive symptoms at baseline also associated with reduced improvement in disease activity over the course of follow-up. Patients with a history of depression or reporting symptoms of depression according to the EuroQol five-dimension scale showed reduced improvement in tender and swollen joints, patient global assessment and ESR over 1-year follow-up. Patients with depression symptoms according to the 36-item Short Form showed reduced improvement in tender and swollen joints, but not ESR or patient global assessment. CONCLUSION: Experiencing symptoms of depression at the start of biologics treatment may reduce the odds of achieving a good treatment response, and reduce improvement in disease activity over time. Depression should be managed as part of routine clinical care to optimize treatment outcomes.
引用
- Matcham F, Davies R, Hotopf M, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2018. PMID: 29447376. doi:10.1093/rheumatology/kex528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。